Sequoia Pharmaceuticals
| Institution is inactive | |
| Legal form | Inc. |
| Founder | Bernard Gilly |
| Founding date | 2002 |
| Liquidation date | 18.11.2013 |
| Headquarters | Gaithersburg, Maryland |
| Website | http://www.sequoiapharmaceuticals.com/ |
Connections
Sequoia Pharmaceuticals
- Mit-investor (Series B&C) -
Wellcome Trust
Participants in the 2005 financing rounds (SeriesB) and 2007 (Seriesc) for the development of antiviral active ingredients.
Sequoia Pharmaceuticals
- Founder & CSO -
John W. Erickson
John Erickson founded Sequoia Pharmaceuticals 2002, previously AIDS researcher, and was Chief Scientific Officer until at least 2007.
Sequoia Pharmaceuticals
- CEO (2007) -
Steven D. Skolsky
Steven Skolsky became CEO of Sequoia Pharmaceuticals and member of the Board of Directors in October 2007.
Sequoia Pharmaceuticals
- HIV-Proteease inhibitor -
SPI‑256
Sequoia clinical preschool candidate (Phasei), first VIH-Protease inhibitor program, submitted in 2007.
Sequoia Pharmaceuticals
- Pharmacokinetic amplifier (PKE) -
SPI‑452
Sequoia's active ingredient candidate ("Booster"), used in clinical phasei together with SPI - 256.
Sequoia Pharmaceuticals
- Investor (Series B) -
HealthCare Ventures
Leading investor in 2005–2007, Seriesb (22mousd) and Seriesc (35mousd) led financing rounds.
Sequoia Pharmaceuticals
- Co -founder & investor -
Bernard Gilly
No information yet.
Sequoia Pharmaceuticals
- Assigne -
Patent US7151163B2 - Antiviral agents for the treatment, control and prevention of infections by coronaviruses
No information yet.